<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>AI in Oncology &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/ai-in-oncology/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 18 Jan 2026 23:57:11 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>AI in Oncology &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>AI Agents Transforming Cancer Research and Treatment</title>
		<link>https://bioengineer.org/ai-agents-transforming-cancer-research-and-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 18 Jan 2026 23:56:45 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AI Ethics** * **AI Agents:** Makalenin ana konusu]]></category>
		<category><![CDATA[AI in Oncology]]></category>
		<category><![CDATA[autonomous medical agents]]></category>
		<category><![CDATA[cancer research]]></category>
		<category><![CDATA[clinical AI integration]]></category>
		<category><![CDATA[İşte içerikle en uyumlu 5 etiket]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[özerk veya yarı-özerk çalışan AI sistemleri. * **Cancer Research:** AI ajanlarının dönüştürücü etkis]]></category>
		<category><![CDATA[personalized cancer therapy]]></category>
		<category><![CDATA[personalized treatment]]></category>
		<category><![CDATA[virgülle ayrılmış şekilde: **AI Agents]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ai-agents-transforming-cancer-research-and-treatment/</guid>

					<description><![CDATA[In the ever-evolving landscape of artificial intelligence, a seismic shift has been observed since 2022, particularly in how AI is applied within the realms of data classification and prediction. Large language models (LLMs), which initially garnered attention for their text generation capabilities, have now entered a new phase where they exhibit logical reasoning skills. This [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318080</post-id>	</item>
		<item>
		<title>MicroRNAs in Cancer: AI-Driven Translational Insights</title>
		<link>https://bioengineer.org/micrornas-in-cancer-ai-driven-translational-insights/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 15 Jan 2026 18:30:24 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AI in Oncology]]></category>
		<category><![CDATA[cancer biomarkers]]></category>
		<category><![CDATA[MicroRNAs in Cancer]]></category>
		<category><![CDATA[personalized cancer therapy]]></category>
		<category><![CDATA[translational medicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/micrornas-in-cancer-ai-driven-translational-insights/</guid>

					<description><![CDATA[Over the past thirty years, the landscape of molecular biology has been transformed by the discovery and exploration of microRNAs (miRNAs), diminutive RNA molecules with outsized regulatory power. Initially identified as critical players in gene regulation, miRNAs have since been implicated in the complex pathogenesis of numerous diseases, most notably cancer. This progression from fundamental [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">317286</post-id>	</item>
		<item>
		<title>AI Advances in Head and Neck Tumor Imaging</title>
		<link>https://bioengineer.org/ai-advances-in-head-and-neck-tumor-imaging/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Oct 2025 15:06:06 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AI in Oncology]]></category>
		<category><![CDATA[Head and Neck Cancer Diagnostics]]></category>
		<category><![CDATA[Medical Imaging Meta-Analysis]]></category>
		<category><![CDATA[PET/CT Imaging Modalities]]></category>
		<category><![CDATA[Tumor Segmentation Techniques]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ai-advances-in-head-and-neck-tumor-imaging/</guid>

					<description><![CDATA[In a groundbreaking advance for oncological imaging, a recent study intensifies the spotlight on artificial intelligence (AI) as an indispensable tool in the precise segmentation of head and neck tumors. Published in the esteemed journal BMC Cancer, this comprehensive systematic review and meta-analysis scrutinizes the comparative efficacies of AI-based tumor delineation across two pivotal imaging [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287138</post-id>	</item>
		<item>
		<title>AI System Revolutionizes Bone Metastases Detection via CT</title>
		<link>https://bioengineer.org/ai-system-revolutionizes-bone-metastases-detection-via-ct/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 13 May 2025 18:03:47 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[AI in Oncology]]></category>
		<category><![CDATA[Bone Metastases Detection]]></category>
		<category><![CDATA[Clinical Workflow Standardization]]></category>
		<category><![CDATA[CT Scan Advancements]]></category>
		<category><![CDATA[deep learning in medical imaging]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ai-system-revolutionizes-bone-metastases-detection-via-ct/</guid>

					<description><![CDATA[In a groundbreaking advance poised to revolutionize oncological diagnostics, a team of researchers has unveiled an artificial intelligence (AI) system capable of accurately detecting and diagnosing bone metastases using computed tomography (CT) scans. This novel technology, detailed in a recent publication in Nature Communications, is designed not only to augment radiologists’ abilities but also to [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">244810</post-id>	</item>
		<item>
		<title>City of Hope to Showcase Breakthroughs in AI, Precision Medicine, and Immunotherapy at AACR Annual Meeting 2025</title>
		<link>https://bioengineer.org/city-of-hope-to-showcase-breakthroughs-in-ai-precision-medicine-and-immunotherapy-at-aacr-annual-meeting-2025/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 17 Apr 2025 18:24:26 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AI in Oncology]]></category>
		<category><![CDATA[cancer research community engagement]]></category>
		<category><![CDATA[immunotherapy breakthroughs]]></category>
		<category><![CDATA[multiomics integration]]></category>
		<category><![CDATA[precision medicine advancements]]></category>
		<guid isPermaLink="false">https://bioengineer.org/city-of-hope-to-showcase-breakthroughs-in-ai-precision-medicine-and-immunotherapy-at-aacr-annual-meeting-2025/</guid>

					<description><![CDATA[City of Hope, a leading institution in cancer research and treatment, is set to showcase a wide array of groundbreaking studies and clinical advances at the upcoming AACR Annual Meeting 2025 in Chicago. This prestigious conference, held from April 25 to April 30, will feature more than 74 sessions chaired by City of Hope experts, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">241416</post-id>	</item>
		<item>
		<title>Announcing the ESMO Sarcoma and Rare Cancers Congress 2025: A Key Event for Advancements in Oncology</title>
		<link>https://bioengineer.org/announcing-the-esmo-sarcoma-and-rare-cancers-congress-2025-a-key-event-for-advancements-in-oncology/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 14 Mar 2025 15:47:50 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AI in Oncology]]></category>
		<category><![CDATA[Cancer immunotherapy advancements]]></category>
		<category><![CDATA[ESMO Sarcoma Congress 2025]]></category>
		<category><![CDATA[Rare Cancers Clinical Trials]]></category>
		<category><![CDATA[Rare Solid Tumor Treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/announcing-the-esmo-sarcoma-and-rare-cancers-congress-2025-a-key-event-for-advancements-in-oncology/</guid>

					<description><![CDATA[Lugano, Switzerland, is set to host a pivotal event in the field of oncology, the ESMO Sarcoma and Rare Cancers Congress 2025, from March 20 to March 22. This congress is poised to be a gathering of leading experts and researchers focusing on one of the most challenging areas in cancer treatment: rare solid tumors. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">238436</post-id>	</item>
	</channel>
</rss>
